Dr. Mell on Risk Stratification for Head and Neck Cancer

Loren K. Mell, MD
Published: Tuesday, Nov 07, 2017



Loren K. Mell, MD, assistant professor, Department of Radiation Medicine and Applied Sciences, University of California, San Diego School of Medicine, discusses risk stratification for patients with head and neck cancer.

According to Mell, it is important to understand which patients are likely to benefit from more or less intensive therapies.

Researchers are undergoing efforts to make staging patients more mathematical, explains Mell. Staging is used to get a sense for how extensive the cancer is and which treatment option will be most beneficial.

SELECTED
LANGUAGE


Loren K. Mell, MD, assistant professor, Department of Radiation Medicine and Applied Sciences, University of California, San Diego School of Medicine, discusses risk stratification for patients with head and neck cancer.

According to Mell, it is important to understand which patients are likely to benefit from more or less intensive therapies.

Researchers are undergoing efforts to make staging patients more mathematical, explains Mell. Staging is used to get a sense for how extensive the cancer is and which treatment option will be most beneficial.


View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Medical Crossfire®: How Can We Optimize Outcomes in Head and Neck Cancers with Immunotherapeutic Strategies?Oct 31, 20191.5
Community Practice Connections™: ASCO Direct™ Highlights – 2019 Official Annual Meeting ReviewAug 30, 20201.5
Publication Bottom Border
Border Publication
x